{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T12:04:18Z","timestamp":1753358658551},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"suppl_D","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1093\/eurheartj\/sux007","type":"journal-article","created":{"date-parts":[[2017,5,16]],"date-time":"2017-05-16T13:35:24Z","timestamp":1494941724000},"page":"D70-D88","source":"Crossref","is-referenced-by-count":5,"title":["ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives"],"prefix":"10.1093","volume":"19","author":[{"given":"Federico","family":"Nardi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele Massimo","family":"Gulizia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Furio","family":"Colivicchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio Giuseppe","family":"Abrignani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania Angela","family":"Di Fusco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Di Lenarda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Di Tano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Geraci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmine","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Verdecchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iolanda","family":"Enea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,5,2]]},"reference":[{"key":"key\n\t\t\t\t20170725102347_sux007-B1","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s40265-015-0452-4","article-title":"Direct oral anticoagulants for the prevention of stroke in patients with nonvalvular atrial fibrillation: understanding differences and similarities","volume":"75","year":"2015","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170725102347_sux007-B2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/fcp.12091","article-title":"Pharmacology and mechanisms of action of direct oral anticoagulants","volume":"29","year":"2015","journal-title":"Fundam Clin Pharmacol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2015.05.001","article-title":"Direct Oral Anticoagulants (DOACs) in the laboratory: 2015 review","volume":"136","year":"2015","journal-title":"Thromb Res"},{"key":"key\n\t\t\t\t20170725102347_sux007-B4","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.amjcard.2012.11.026","article-title":"Frequency, patient characteristics, treatment strategies, and resource usage of atrial fibrillation (from the Italian Survey of Atrial Fibrillation Management [ISAF] study)","volume":"111","year":"2013","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B5","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","year":"2007","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20170725102347_sux007-B6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","year":"2015","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170725102347_sux007-B7","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170725102347_sux007-B8","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170725102347_sux007-B9","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170725102347_sux007-B10","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"ENGAGE AF-TIMI 48 Investigators","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170725102347_sux007-B11","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170725102347_sux007-B12","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1016\/j.jacc.2013.03.020","article-title":"Efficacy and safety of dabigatran etexilate and warfarin in \u201creal-world\u201d patients with atrial fibrillation: a prospective nationwide cohort study","volume":"61","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1161\/CIRCULATIONAHA.114.012061","article-title":"Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation","volume":"131","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170725102347_sux007-B14","doi-asserted-by":"crossref","first-page":"h1585.","DOI":"10.1136\/bmj.h1585","article-title":"Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study","volume":"350","year":"2015","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170725102347_sux007-B15","doi-asserted-by":"crossref","first-page":"h1857.","DOI":"10.1136\/bmj.h1857","article-title":"Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study","volume":"350","year":"2015","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20170725102347_sux007-B16","doi-asserted-by":"crossref","first-page":"e001798.","DOI":"10.1161\/JAHA.115.001798","article-title":"Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study","volume":"4","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20170725102347_sux007-B17","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1160\/TH09-11-0758","article-title":"Dabigatran etexilate\u2013a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity","volume":"103","year":"2010","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170725102347_sux007-B18","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s40265-013-0056-9","article-title":"Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation","volume":"73","year":"2013","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170725102347_sux007-B19","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1007\/s40265-013-0063-x","article-title":"Apixaban: a review of its use for reducing the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation","volume":"73","year":"2013","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170725102347_sux007-B20","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2165\/11595540-000000000-00000","article-title":"Edoxaban: a new oral direct factor xa inhibitor","volume":"71","year":"2011","journal-title":"Drugs"},{"key":"key\n\t\t\t\t20170725102347_sux007-B21","article-title":"Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation","year":"2015","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170725102347_sux007-B22","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1331\/JAPhA.2013.12218","article-title":"Dabigatran-dronedarone interaction in a spontaneous reporting system","volume":"53","year":"2013","journal-title":"J Am Pharm Assoc (2003)"},{"key":"key\n\t\t\t\t20170725102347_sux007-B23","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1093\/eurheartj\/ehv201","article-title":"Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B24","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1111\/j.1538-7836.2011.04498.x","article-title":"Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial","volume":"9","year":"2011","journal-title":"J Thromb Haemost"},{"key":"key\n\t\t\t\t20170725102347_sux007-B25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/bcp.12055","article-title":"Semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin","volume":"76","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B26","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s40256-013-0029-0","article-title":"Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor","volume":"13","year":"2013","journal-title":"Am J Cardiovasc Drugs"},{"key":"key\n\t\t\t\t20170725102347_sux007-B27","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","article-title":"Andexanet alfa for acute major bleeding associated with factor Xa inhibitors","volume":"375","author":"ANNEXA-4 Investigators","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170725102347_sux007-B28","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.1161\/CIR.0000000000000041","article-title":"2014 AHA\/ACC\/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society","volume":"130","author":"Members AATF","year":"2014","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170725102347_sux007-B29","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1093\/eurheartj\/ehs253","article-title":"2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association","volume":"33","author":"Guidelines ESCCfP","year":"2012","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/eurheartj\/ehn101","article-title":"Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation?","volume":"29","year":"2008","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B31","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1016\/j.jacc.2007.07.076","article-title":"Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy","volume":"50","author":"Investigators AW","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B32","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1016\/j.ijcard.2012.06.118","article-title":"Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project","volume":"167","year":"2013","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B33","doi-asserted-by":"crossref","first-page":"28.","DOI":"10.1186\/1471-2261-13-28","article-title":"A. Thrombo-embolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial","volume":"13","year":"2013","journal-title":"BMC Cardiovasc Disord"},{"key":"key\n\t\t\t\t20170725102347_sux007-B34","doi-asserted-by":"crossref","first-page":"622.","DOI":"10.1161\/01.STR.17.4.622","article-title":"Embolic complications in paroxysmal atrial fibrillation","volume":"17","year":"1986","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170725102347_sux007-B35","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/eurheartj\/eht135","article-title":"Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B36","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2796.2007.01909.x","article-title":"Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation","volume":"264","year":"2008","journal-title":"J Intern Med"},{"key":"key\n\t\t\t\t20170725102347_sux007-B37","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0002-8703(99)70224-3","article-title":"Lone atrial fibrillation: prognostic differences between paroxysmal and chronic forms after 10 years of follow-up","volume":"137","year":"1999","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B38","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/ageing\/15.2.89","article-title":"Atrial fibrillation and stroke in elderly hospitalized patients","volume":"15","year":"1986","journal-title":"Age Ageing"},{"key":"key\n\t\t\t\t20170725102347_sux007-B39","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.jacc.2011.10.896","article-title":"Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study","volume":"59","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B40","first-page":"60","article-title":"Thrombo-embolic and hemorrhagic risk stratification in patients with atrial fibrillation. Part I: the thrombo-embolic risk","volume":"80","year":"2013","journal-title":"Monaldi Arch Chest Dis"},{"key":"key\n\t\t\t\t20170725102347_sux007-B41","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1093\/europace\/euv068","article-title":"Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation","volume":"17","author":"on behalf of the Writing Committee of the Action for Stroke Prevention alliance","year":"2015","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170725102347_sux007-B42","first-page":"295","article-title":"nome dell\u2019Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO). Documento ANMCO su prevenzione del tromboembolismo nella fibrillazione atriale e ruolo dei nuovi anticoagulanti orali","volume":"14","year":"2013","journal-title":"G Ital Cardiol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B43","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/ejcts\/ezw313","article-title":"2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS","volume":"50","year":"2016","journal-title":"Eur J Cardiothorac Surg"},{"key":"key\n\t\t\t\t20170725102347_sux007-B44","first-page":"283","article-title":"Practical and clinical considerations in assessing patients with atrial fibrillation for switching to non-vitamin K antagonist oral anticoagulants in primary care","volume":"8","year":"2015","journal-title":"Int J General Med"},{"key":"key\n\t\t\t\t20170725102347_sux007-B45","first-page":"244","article-title":"Meta-analysis to assess the quality of warfarin control in atrial fibrillation patients in the United States","volume":"15","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"key\n\t\t\t\t20170725102347_sux007-B46","doi-asserted-by":"crossref","first-page":"d124.","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thrombo-embolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","year":"2011","journal-title":"Br Med J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B47","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/01.STR.14.4.537","article-title":"Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease","volume":"14","year":"1983","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170725102347_sux007-B48","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","year":"2016","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170725102347_sux007-B49","first-page":"123","article-title":"Terapia anticoagulante orale della fibrillazione atriale in Italia: a che punto siamo?","volume":"15","year":"2014","journal-title":"G Ital Cardiol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B50","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1093\/eurheartj\/ehu307","article-title":"Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B51"},{"key":"key\n\t\t\t\t20170725102347_sux007-B52","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1007\/s11239-013-1048-z","article-title":"Estimation of the impact of warfarin\u2019s time-intherapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use - learnings from ARISTOTLE, ROCKET-AF and RE-LY trials","volume":"38","year":"2014","journal-title":"J Thromb Trombolysis"},{"key":"key\n\t\t\t\t20170725102347_sux007-B53","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1001\/jama.1950.02910450010003","article-title":"Prophylaxis of recurrent embolism of intracardiac origin; protracted anticoagulant therapy. On an ambulatory basis","volume":"143","year":"1950","journal-title":". J Am Med Assoc"},{"key":"key\n\t\t\t\t20170725102347_sux007-B54","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","year":"1991","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170725102347_sux007-B55","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1093\/eurheartj\/ehi505","article-title":"Atrial fibrillation management: a prospective survey in ESC Member Countries. The Euro Heart Survey on Atrial Fibrillation","volume":"26","year":"2005","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B56","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/hrt.24.3.349","article-title":"The natural history of 271 patients with mitral stenosis under medical treatment","volume":"24","year":"1962","journal-title":"Br Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B57","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.ijcard.2012.07.019","article-title":"Current presentation and management of 7148 patients with atrial fibrillation in cardiology and internal medicine hospital centers: the ATA AF study","volume":"167","year":"2013","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B58"},{"key":"key\n\t\t\t\t20170725102347_sux007-B59","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.amjcard.2012.03.021","article-title":"Usefulness of continuasi ECG monitorin fora trial fibrillation","volume":"110","year":"2012","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B60","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1093\/eurheartj\/ehu305","article-title":"Clinical characteristics and outcomes with rivaroxaban vs warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease partecipating in the ROCKET AF Trial","volume":"35","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B61","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1161\/CIRCULATIONAHA.114.014807","article-title":"Apixaban in comparison with warfarin in patients with atrial fibrillation and valvular heart disease: findings from the Apixaban for Reduction in Stroke and Other Thrombo-embolic Events in Atrial Fibrillation (ARISTOTLE) trial","volume":"132","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20170725102347_sux007-B62","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1056\/NEJMoa1300615","article-title":"Dabigatran versus warfarin in patients with mechanical heart valves","volume":"369","year":"2013","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20170725102347_sux007-B63","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/europace\/euq350","article-title":"Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). European Heart Rhythm Association1; European Association for Cardio-Thoracic Surgery","volume":"12","year":"2010","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170725102347_sux007-B64","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ahj.2004.06.032","volume":"149","year":"2005","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B65","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/eurheartj\/eht096","article-title":"A proposal for interdisciplinary, nurse coordinated atrial fibrillation expert programmes as a way to structure daily practice","volume":"34","year":"2013","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B66","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehn599","article-title":"Ictus in paroxysmal atrial fibrillation: report from the stockholm cohort of atrial fibrillation","volume":"31","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B67","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.jstrokecerebrovasdis.2011.04.010","article-title":"Pilot Study of cardiac magnetic resonance imaging for detection of embolic source after ischemic stroke","volume":"21","year":"2012","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"key\n\t\t\t\t20170725102347_sux007-B68","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/pace.12264","article-title":"Evaluation of time course and predicting factors of progression of paroxysmal or persistent atrial fibrillation to permanent atrial fibrillation","volume":"37","year":"2014","journal-title":"Pacing Clin Electrophysiol"},{"key":"key\n\t\t\t\t20170725102347_sux007-B69","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/j.hrthm.2011.04.022","article-title":"Temporal relationship of atrial tachyarrhythmias, cerebrovascular events, and systemic emboli based on stored device data: a subgroup analysis of TRENDS","volume":"8","year":"2011","journal-title":"Heart Rhythm"},{"key":"key\n\t\t\t\t20170725102347_sux007-B70","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1378\/chest.09-1584","article-title":"Refining clinical risk stratification for predicting stroke and thrombo-embolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation","volume":"137","year":"2010","journal-title":"Chest"},{"key":"key\n\t\t\t\t20170725102347_sux007-B71","first-page":"749","article-title":"Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial","volume":"380","year":"2012","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20170725102347_sux007-B72","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1161\/01.STR.30.9.1991","article-title":"Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for Healthcare professionals from the Stroke Council of the American Heart Association","volume":"30","year":"1999","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20170725102347_sux007-B73","first-page":"483","volume-title":"Fibrillazione atriale in Linee Guida SIEC","year":"2009"},{"key":"key\n\t\t\t\t20170725102347_sux007-B74","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/eurheartj\/ehq005","article-title":"Imaging and atrial fibrillation: the role of multimodality imaging in patient evaluation and management of atrial fibrillation","volume":"31","year":"2010","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20170725102347_sux007-B75","year":"2013"},{"key":"key\n\t\t\t\t20170725102347_sux007-B76","doi-asserted-by":"crossref","first-page":"57.","DOI":"10.1186\/1471-2318-10-57","article-title":"A frailty instrument for primary care: findings from the Survey of Health, Ageing and Retirement in Europe (SHARE)","volume":"10","year":"2010","journal-title":"BMC Geriatr"},{"key":"key\n\t\t\t\t20170725102347_sux007-B77","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1160\/TH14-04-0305","article-title":"Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial","volume":"113","year":"2015","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20170725102347_sux007-B78","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/europace\/eup124","article-title":"Early and comprehensive management of atrial fibrillation: preceedings from the 2nd AFNET\/EHRA consensus conference on atrial fibrillation entitled \u201cresearch perspectives in atrial fibrillation\u201d","volume":"11","year":"2009","journal-title":"Europace"},{"key":"key\n\t\t\t\t20170725102347_sux007-B79","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1502000","article-title":"Idarucizumab for dabigatran reversal","volume":"373","year":"2015","journal-title":"N Engl J Med"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/19\/suppl_D\/D70\/19286193\/sux007.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,24]],"date-time":"2019-09-24T18:23:54Z","timestamp":1569349434000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article-lookup\/doi\/10.1093\/eurheartj\/sux007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":79,"journal-issue":{"issue":"suppl_D","published-online":{"date-parts":[[2017,5,2]]},"published-print":{"date-parts":[[2017,5]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/sux007","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}